Omentin-1 as a promising biomarker and therapeutic target in hypertension and heart failure: a comprehensive review
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04008-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Mohammad Yasin Zamanian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, 6718773654, Iran. m.zamanian@umsha.ac.ir. Hauptthemen laut MEDLINE: Hypertension, Heart Failure, Cytokines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 133 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Omentin-1, a novel adipocytokine predominantly secreted by visceral adipose tissue, has emerged as a significant factor in cardiovascular health, particularly regarding hypertension (HTN) and heart failure (HF). This manuscript investigates the multifaceted roles of omentin-1 in these conditions, emphasizing its protective effects on vascular function and its potential as both a biomarker and therapeutic target. Clinical studies indicate that reduced circulating levels of omentin-1 are associated with metabolic syndrome (MetS) and increased cardiovascular risk, while animal studies demonstrate its ability to ameliorate endothelial dysfunction and lower blood pressure. Omentin-1 exerts its beneficial effects through various signaling pathways, including AMP-activated protein kinase (AMPK) and protein kinase B (Akt), thereby promoting vasodilation, enhancing insulin sensitivity, and mitigating inflammation. In the context of HF, particularly heart failure with preserved ejection fraction (HFpEF), omentin-1 levels exhibit a negative correlation with diastolic dysfunction and inflammatory markers, suggesting its role in cardiac protection. Additionally, the manuscript discusses the implications of omentin-1 in managing obesity-related cardiovascular diseases and its potential utility as a prognostic marker for adverse outcomes in HF patients. Collectively, omentin-1 represents a promising avenue for research in cardiovascular health, with the potential to inform novel therapeutic strategies aimed at improving outcomes in patients with HTN and HF. Further research is necessary to elucidate the details of omentin-1 function and evaluate its potential in the treatment of cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, 6718773654, Iran. m.zamanian@umsha.ac.ir.
- Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, 6718773654, Iran. m.zamanian@umsha.ac.ir.
- Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Guilan University of Medical Sciences (GUMS), Rasht, Guilan Province, Iran.
- Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmacy, Delta State University, Abraka, Nigeria.
- Directorate of Sports and Physical Education, University of Jammu, Jammu, India.
Zitieren
APA
Zamanian, M. Y., Maleki, S., Oghenemaro, E. F., Singh, M., Mohammadi, M., Alkhayyat, A. H., Sapaev, I. B., Kaur, P., Shirsalimi, N., & Nagarwal, A. (2025). Omentin-1 as a promising biomarker and therapeutic target in hypertension and heart failure: a comprehensive review. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04008-y
Vancouver
Zamanian MY, Maleki S, Oghenemaro EF, Singh M, Mohammadi M, Alkhayyat AH, et al. Omentin-1 as a promising biomarker and therapeutic target in hypertension and heart failure: a comprehensive review. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04008-y
BibTeX
@article{Zamanian2025,
author = {Zamanian, Mohammad Yasin and Maleki, Saba and Oghenemaro, Enwa Felix and Singh, Mandeep and Mohammadi, Maryam and Alkhayyat, Ahmad Hussen and Sapaev, Ibrokhim B and Kaur, Parjinder and Shirsalimi, Niyousha and Nagarwal, Amritesh},
title = {Omentin-1 as a promising biomarker and therapeutic target in hypertension and heart failure: a comprehensive review},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04008-y}
}
EUVIMED